创始人
王喆 博士
创始人、董事长
王喆博士师从诺贝尔化学奖得主 E.J. Corey教授，从事药物开发研究工作20余年，有领导从立项到药物上市的完整产业链经验，在抗感染、抗病毒及抗癌新药研发领域有极深的造诣与卓越成就。
Founder
Dr. Zhe WANG
Founder, chairman
Dr. Zhe WANG studied under Prof. E.J. Corey, a Nobel laureate in chemistry.
With more than 20 years engaged in drug research and development, Dr. Zhe WANG has full experience of leading drug development from project initiation to drug launch. He has profound attainments and outstanding achievements in the field of new drug of anti-infection, anti-virus and anti-cancer.
研发体系
长森药业聚焦自身免疫疾病、肿瘤免疫治疗、抗病毒等领域的创新药研发与产业化，管线产品临床评估指标均达到国际领先水平，有望成为相关领域的重大突破（FIC，first in class）。
长森药业专注具有自主知识产权及国际领先水平的创新药物的开发和医学转化，通过合作开发、Licensing Out等形式，积极参与国际竞争，解决尚未满足的临床需求。
R&D
Longwood Biopharma is focusing on the development and industrialization of innovative drugs in the fields of autoimmune diseases, tumor immunotherapy and anti-virus. With world-class performance in clinical evaluation, our pipelines are expected to become a major breakthrough in related fields (FIC, first in class).
Longwood Biopharma focuses on the development and medical translation of world-class innovative drugs with independent IPR, and actively participates in international competition through co-development and licensing-out to address unmet clinical needs.
新闻资讯
【长森快讯】公司创始人王喆博士受邀参加BIO-FORUM2025会前闭门会：生物医药颠覆性技术研讨会并做主题分享
近日，长森药业创始人王喆博士受邀参加BIO-FORUM2025会前闭门会：生物医药颠覆性技术研讨会，并在活动中作“双功能-双靶点潜在完全治愈乙肝药物的开发与产业化”主题分享。...
【长森快讯】长森药业B+轮融资数亿元，加速推进核心管线临床研究与全球化布局
日前，上海长森药业有限公司（下称“长森药业”）宣布完成数亿元人民币B+轮融资，本轮融资由启明创投领投。
【长森快讯】全球首款双功能-双靶点乙肝完全治愈一类新药LW231 Ib/II期临床正式启动
近日，由长森药业自主研发的全球首款双功能双靶点乙肝完全治愈类Ⅰ类新药LW231，其Ib/II期多中心临床研究正式启动。
News
【LWBP News】Dr. Zhe Wang Invited to Attend the Pre-Conference Meeting of BIO-FORUM2025 and Deliver a Keynote Speech
Recently, Dr. Zhe Wang, Founder of Longwood Biopharmaceuticals, was invited to attend the Pre-Conference Meeting of BIO-FORUM2025 - Symposium on Disruptive Technologies in Biomedical Industry and delivered a keynote speech...
【LWBP NEWS】【LWBP NEWS】Longwood Biopharmaceuticals Secures Hundreds of Millions of RMB in Series B+ Financing to Accelerate Core Pipeline Clinical Research and Global Layout
Recently, Shanghai Longwood Biopharmaceuticals Co., Ltd. (hereinafter referred to as “Longwood Biopharmaceuticals”) announced the completion of its Series B+ financing round, raising hundreds of millions of RMB. Qiming Venture Partners led this round of investment.
【LWBP NEWS】 World's First Bi-functional, Dual-Target Drug for Complete Cure of Hepatitis B, LW231 Officially Initiates Phase Ib/II Clinical Trial
Recently, the Phase Ib/II multi-center clinical trial of LW231, the world's first dual-function, dual-target Class 1 new drug for the complete cure of hepatitis B independently developed by Longwood Biopharmaceuticals, was officially initiated.
